CTOs on the Move

The Arc Northern Chesapeake Region

www.arcncr.org

 
For over 70 years, The Arc Northern Chesapeake Region (The Arc NCR) has empowered people with differing abilities to live, work and thrive in the community. The Arc NCR currently offers the following services to people with differing abilities living in Harford and Cecil Counties: Community Living Community Partners Employment Services Family Support Services Personal Supports Treatment Foster Care Our Mission The Arc NCR empowers people with differing abilities to live, work and thrive in the community. Our Vision A world where people with differing abilities lead personally valued lives. Our Tagline Advocate. Educate. Participate. The Arc NCR supports people with intellectual and/or developmental disabilities to create lives that mirror ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.arcncr.org
  • 4513 Philadelphia Rd
    Aberdeen, MD USA
  • Phone: 410.836.7177

Executives

Name Title Contact Details

Similar Companies

BTB Solution

BTB Solution is a Seoul, IL-based company in the Business Services sector.

Mobius Cre

Mobius Cre is a San Diego, CA-based company in the Business Services sector.

Ingenium Technologies

Ingenium Technologies is a Rockford, IL-based company in the Business Services sector.

Central Texas Avionics Inc

Central Texas Avionics Inc is a Georgetown, TX-based company in the Business Services sector.

Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.